CAN 508

Known as: CAN-508, CAN508 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2017
01220062017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The cyclin-dependent kinase inhibitor, CAN508, was protected with di-tert-butyl dicarbonate to access the amino-benzoylated… (More)
Is this relevant?
2017
2017
A general and efficient synthesis of 4-substituted-1H-pyrazole-3,5-diamines was developed to access derivatives with an aryl… (More)
Is this relevant?
2017
2017
Role of cyclin dependent kinase 9(CDK9) as a potential target in esophageal adenocarcinoma (EAC) is unknown. We investigated CDK9… (More)
Is this relevant?
2015
2015
Here, we describe new 4-arylazo-3,5-diamino-1H-pyrazole derivatives developed from CAN508, one of the first inhibitors to show… (More)
Is this relevant?
2012
2012
CDK9 is the kinase of positive transcription elongation factor b and facilitates the transition of paused RNA polymerase II to… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2011
2011
Small molecule inhibitors of cyclin-dependent kinases (CDK) have been developed as anticancer drugs with cytostatic and cytotoxic… (More)
Is this relevant?
2006
2006
In a routine screening of our small-molecule compound collection we recently identified 4-arylazo-3,5-diamino-1H-pyrazoles as a… (More)
Is this relevant?